Early Life Intervention in Pediatrics Supported by E-health - SMOKE
Early Life Intervention in Pediatrics Supported by E-health (ELIPSE II): Coaching Parents to Lower Second-hand Smoke Exposure in Children A Single-blind Randomized Controlled Parallel-group Clinical Trial
Insel Gruppe AG, University Hospital Bern
160 participants
May 7, 2024
INTERVENTIONAL
Conditions
Summary
Unrestricted parental smoking habits are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of non-communicable diseases (NCDs). Exposure to secondhand tobacco smoke in early life contributes to the development of specific NCDs in children, i.e. asthma. Early preventive measures to improve lifestyle behavior in parents are therefore of utmost importance. The aim of ELIPSE-II is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering levels of urinary cotinine as a measure of second-hand smoke exposure in their children .
Eligibility
Inclusion Criteria7
- Age: younger than 6 years
- Exposed to second-hand smoke at home (at least one parent smoking)
- German speaking parent
- All sex and ethnic backgrounds
- Signed informed consent form from parent
- Children live/grow-up in the same household as the parental participant
- Referred by a health care professional (e.g. physician, midwife, nurse, other professions)
Exclusion Criteria2
- Participation in another study/trial targeting similar outcomes
- Participation in an active smoking cessation programme
Interventions
The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06311162